D’heygere F, George C, Habersetzer F, Tripathi D, Pan CQ, Giron JA, Schmitz M, Tatsch F

Language: English
References: 5
Page: 303-304
PDF size: 66.14 Kb.

Text Extraction

Infection with hepatitis C virus (HCV) genotype (G)5 or G6 is relatively uncommon worldwide, with data on the efficacy of peginterferon/ribavirin (PegIFN/ RBV) treatment limited, and sometimes contradictory compared with other HCV genotypes. G5 is predominantly found in South Africa, with local clusters reported in France, Spain, Syria, Belgium and Canada, while G6 has been reported in Asian countries and patients of Asian origin in the US and Canada.4 Here, we report data from the 25 G5 and G6 patients from the “real world” PROPHESYS study5 receiving PegIFN alfa-2a (40KD) (PEGASYS^®, Roche, Basel, Switzerland) plus RBV.

REFERENCES

1. D’heygere F, George C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M, Delwaide J, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol 2011; 83: 815-19.

2. Lam KD, Trinh HN, Do ST, Nguyen TT, Garcia RT, Nguyen T, Phan QQ, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010; 52: 1573-80.

3. Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Alshuth U, Rockstroh JK, Niederau C, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012; 50: 441-4.

4. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30: 342-55.

5. Marcellin P, Cheinquer H, Curescu M, Dusheiko G, Ferenci P, Horban A, Jensen D, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56: 2039-50.